We serve Chemical Name:1-Chlorododecane CAS:112-52-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-Chlorododecane
CAS.NO:112-52-7
Synonyms:chlorododecane;dodeceyl chloride;Dodecyl chloride;Dodecane,1-chloro;Dodecane, 1-chloro-;chloro-1-dodecane;1-chloro-dodecane;1-Chlorododecane;EINECS 203-981-5;n-Dodecyl chloride;MFCD00013688;Lauryl chloride
Molecular Formula:C12H25Cl
Molecular Weight:204.780
HS Code:29189090
Physical and Chemical Properties:
Melting point:-9.3 °C
Boiling point:260.4±3.0 °C at 760 mmHg
Density:0.9±0.1 g/cm3
Index of Refraction:1.438
PSA:
Exact Mass:204.164474
LogP:6.81
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3082 9/PG 3
Packing Group:
Contact us for information like chlorododecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Lauryl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-chloro-dodecane Use and application,MFCD00013688 technical grade,usp/ep/jp grade.
Related News: In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. 1-Chlorododecane manufacturer Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 1-Chlorododecane supplier After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing. 1-Chlorododecane vendor Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 1-Chlorododecane factory The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively).
